MiNK Therapeutics (INKT) announced the appointment of Colonel Ret. John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases
- Mink Therapeutics’ Earnings Call: Clinical Progress Amid Financial Challenges
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating
- MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright